Gastrointestinal (GI) tumors are among the leading cause of death in cancer patients
worldwide. Particularly, gastric cancer (GC) is the third cause of cancer deaths, whereas esophageal
neoplasm is the eighth leading most common cancer worldwide and its incidence, especially adenocarcinoma
type, is continuously increasing. Also, Hepatocellular carcinoma, Cholangiocarcinoma
and pancreatic cancer represent a very interesting model to multidisciplinary approach and recently
new drugs are used in their treatment. Currently, new clinical trials are designed including classic
chemotherapy in association with either small molecule inhibitors (i.e. Tyrosine Kinase inhibitors)
and/or monoclonal antibody (i.e. anti-EGFR antibody). Moreover, a comprehensive list of new
molecules for target therapy is included in this issue. The development of new treatment modalities
(multidisciplinary approach) and targeted therapy approaches have contributed to improving the outcome
in these cancer diseases. During the past few years, remarkable progress in molecular biology
of malignancy, the discovery of specific targets, and the resulting development of systemic drugs
that block critical kinases and several molecular pathways have all contributed to progress in cancer
treatment, also in GI non-colorectal cancer treatment.
Keywords: Gastrointestinal cancers, target therapy, clinical aspects, treatment, prognostic factors, metastases, costs.
Rights & PermissionsPrintExport